Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US

New Delhi: The global biopharmaceuticals major, Biocon has announced the launch of Tacrolimus capsules in the United States.

Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades.

As per company, the launch of Tacrolimus capsules, following approval from the US FDA in November 2020, underscores the relentless pursuit of its mission to make affordable healthcare accessible.

Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon, said: “The launch of Tacrolimus capsules in the US is another milestone for Biocon that reflects our commitment to continually evaluate and expand our portfolio of complex products to serve patients.”